CURRENT CONCEPTS - GUIDELINES FOR THE USE OF THROMBOLYTIC AGENTS

被引：189

作者：

BELL, WR ^{[1
]}

MEEK, AG ^{[1
]}

机构：

[1] JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21205

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1979年 / 301卷 / 23期

关键词：

D O I：

10.1056/NEJM197912063012305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

TWO agents that induce thrombolytic activity have recently been approved for clinical use by the Food and Drug Administration: streptokinase (marketed as Streptase by Hoechst-Roussel Pharmaceuticals, Somerville, NJ, and as Kabikinase by Kabi Group, Greenwich, CT) and urokinase (marketed as Abbokinase by Abbott Laboratories, North Chicago, IL).1 These drugs activate plasminogen and thus cause the formation of the proteolytic enzyme plasmin. (Other agents with the potential for activating the human fibrinolytic system include Thrombolysin and Actase. These drugs are mixtures of streptokinase, plasminogen, activator complex, and plasmin and have not been subjected to controlled trials in thromboembolic disease.) Clinical studies. © 1979, Massachusetts Medical Society. All rights reserved.

引用

页码：1266 / 1270

页数：5

共 41 条

[21]

LY B, 1978, ACTA MED SCAND, V203, P465

[22] GUIDELINES FOR THROMBOLYTIC THERAPY OF DEEP-VEIN THROMBOSIS [J].